Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fresenius Medical Care ( (FMS) ) has shared an announcement.
On November 4, 2025, Fresenius Medical Care announced its third-quarter results, highlighting a 28% growth in operating income and a 10% increase in organic revenue. The company reported significant progress in its FME Reignite strategy, achieving substantial savings and advancing its share buyback program. Despite divestments affecting revenue, the company confirmed its full-year outlook, indicating a positive trajectory in financial performance and strategic initiatives.
The most recent analyst rating on (FMS) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.
Spark’s Take on FMS Stock
According to Spark, TipRanks’ AI Analyst, FMS is a Outperform.
Fresenius Medical Care’s overall stock score is driven by strong earnings call performance and stable financial health. While the company shows robust revenue and cash flow growth, challenges like high debt reliance and external cost pressures temper the outlook. Technical indicators suggest a neutral market sentiment, and valuation metrics are reasonable but not exceptional.
To see Spark’s full report on FMS stock, click here.
More about Fresenius Medical Care
Fresenius Medical Care is a leading global provider of products and services for individuals with renal diseases. The company focuses on delivering dialysis services and products, with a strong market presence in the healthcare industry.
Average Trading Volume: 328,062
Technical Sentiment Signal: Buy
Current Market Cap: $15.27B
See more data about FMS stock on TipRanks’ Stock Analysis page.